Mitra K Nadim, MD, FASN

Professor Of Clinical Medicine

Director of Critical Care Nephrology

Image of Mitra K Nadim, MD, FASN
Is this your profile? Click to edit

Overview

After graduating from UCLA Medical School, Dr. Nadim went to Boston for her internship and residency at the prestigious Beth Israel Hospital, which is affiliated with Harvard University’s School of Medicine. After completing a nephrology fellowship at Brigham and Women’s/Massachusetts General Hospital, Harvard University, Dr. Nadim returned to Southern California and currently serves as Professor of Clinical Medicine and Director of USC’s Hypertension Center. Dr. Nadim served as the Associate Program Director for the Nephrology Fellowship Program from 2003 – 2006.

Dr. Nadim’s major clinical and research interests concerns the diagnosis and management of resistant hypertension. she is currently one of the National Principal Investigators in the Rheos Pivitol Trial, which is a multicenter clinical trial looking at efficacy and safety of the Rheos system, an implantable baroreflex device, in subjects with resistant hypertension.

Dr. Nadim’s clinical areas of expertise:

HYPERTENSION CLINIC

Dr. Nadim is a clinical specialist in hypertension and Director of the USC Hypertension Center. She has been an investigator in several hypertension studies, and her clinical practice has a special emphasis on resistant hypertension.

Awards

  • Golden Key National Honor Society: Member, 1988
  • University of California, Irvine: Phi Beta Kappa, 1989
  • University of California, Irvine: Cum Laude, 1990
  • University of California, Irvine: Excellence in Research Award, 1990
  • National Kidney Foundation: Volunteer/Donor Award, 1999
  • Alpha Omega Alpha: Research Fellowship Award, 1992
  • National Institutes of Health: National Research Service Award, 1999
  • Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2004
  • Keck School of Medicine of USC: Medical Faculty Women’s Award Research Grant, 2007
  • Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2007
  • Rheos Pivitol Trial: National Principal Investigator, 2008
  • Keck School of Medicine of USC: Outstanding Year II Course Award, 2008
  • Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2011
  • Keck School of Medicine of USC: Master Teacher Award, 2011
  • Keck School of Medicine: Faculty Teaching Award, 2012
  • Keck School of Medicine of USC: Outstanding Year II Course Award, 2013
  • Keck School of Medicine of USC: Faculty Teaching Award, 2015

Publications

  • Erratum: Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2025 Dec 01; 82(6):E160.. View in PubMed
  • From protocol to precision: The evolving diagnosis of hepatorenal syndrome. J Hepatol. 2026 Jan; 84(1):e19-e21.. View in PubMed
  • Reply to: “Inclusion of patients with active urinary sediment in treatment of hepatorenal syndrome”. J Hepatol. 2025 Jul; 83(1):e43-e44.. View in PubMed
  • The heart-kidney axis in cirrhosis: rethinking hepatorenal and cardiorenal syndromes-authors’ reply. Intensive Care Med. 2025 Feb; 51(2):433-434.. View in PubMed
  • Update on Hepatorenal Syndrome: From Pathophysiology to Treatment. Annu Rev Med. 2025 01; 76(1):373-387.. View in PubMed
  • Terlipressin use in hepatorenal syndrome-acute kidney injury in cirrhosis. Author’s reply. Intensive Care Med. 2025 Jan; 51(1):215-216.. View in PubMed
  • Reply to: “Shortening the albumin challenge from 48 to 24 hours may lead to overdiagnosis of hepatorenal syndrome-acute kidney injury and overtreatment with terlipressin”. J Hepatol. 2025 Feb; 82(2):e100-e101.. View in PubMed
  • Terlipressin use in HRS-AKI and respiratory failure. Author’s reply. Intensive Care Med. 2024 10; 50(10):1713-1714.. View in PubMed
  • Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement. Intensive Care Med. 2024 09; 50(9):1426-1437.. View in PubMed
  • Performance of race-neutral eGFR equations in patients with decompensated cirrhosis. Liver Transpl. 2025 02 01; 31(2):170-180.. View in PubMed